Addition of the QW Modifier to Healthcare Common Procedure Coding System (HCPCS) Code 87636

MLN Matters Number: MM12269
Related Change Request (CR) Number: 12269
Related CR Release Date: April 26, 2021
Effective Date: July 1, 2021
Related CR Transmittal Number: R10732OTN
Implementation Date: July 6, 2021

PROVIDER TYPES AFFECTED

This MLN Matters® Article is for physicians, hospitals, laboratories, other providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for HCPCS code 87636 for Medicare patients.

PROVIDER ACTION NEEDED

This article informs you of the addition of the QW modifier to HCPCS code 87636 [Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique]. CMS included HCPCS code 87636 in Transmittal R10575CP (CR 12080) with an effective date of October 6, 2020. Make sure your billing staffs are aware of this change.

BACKGROUND

The Clinical Laboratory Improvement Amendments (CLIA) regulations require a facility to be appropriately certified for each test performed. To ensure Medicare and Medicaid only pay for laboratory tests performed in certified facilities, each claim for an HCPCS code that is considered a CLIA laboratory test is currently edited at the CLIA certificate level.

On February 4, 2020, the HHS Secretary determined there is a Public Health Emergency (PHE) due to COVID-19. During PHEs declared under Section 564 of the Federal Food, Drug, and Cosmetic (FD&C) Act, the FDA may issue Emergency Use Authorizations (EUAs) when certain criteria are met that allows for the use and distribution of potentially life-saving medical products to diagnose, treat, or prevent the disease, which can include diagnostic tests. Currently, there is no FDA-approved or cleared test to diagnose or detect Coronavirus disease 2019. The FDA has issued several In Vitro Diagnostic EUAs for SAR-CoV-2 and Coronavirus disease 2019.

The FDA doesn’t categorize tests authorized under an EUA. The settings in which an EUA-authorized test may be used are described in the Letter of Authorization. The Guidance for
Industry and Other Stakeholders: Emergency Use Authorization of Medical Products and Related Authorities says when the FDA authorizes tests for use at the point of care (including COVID-19 point of care test systems) under an EUA, such tests are deemed to be CLIA waived tests. As such, throughout the COVID-19 PHE, you can perform such tests in a patient care setting qualified to have the test performed there as a result of operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Facilities possessing a current CLIA Certificate of Waiver may conduct In Vitro Diagnostic point of care tests under EUAs listed on the FDA In Vitro Diagnostic EUAs website. The FDA has issued at least one EUA for infectious agent detection by nucleic acid of COVID-19 and influenza virus types A and B using a multiplex amplified probe technique that it authorized for use at the point of care setting. HCPCS code 87636 describes this EUA test.

Claims for tests you perform in facilities having a CLIA certificate of waiver must include the QW modifier. MACs won’t search their files to either retract payment for claims already paid or to retroactively pay claims. However, they will adjust such claims you bring to their attention.

ADDITIONAL INFORMATION

CMS issued CR 12269 to your MAC as the official instruction for this change.

For more information, contact your MAC.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 26, 2021</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2020 American Medical Association. All rights reserved.

Copyright © 2013-2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized in any software product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 manual and/or codes and descriptions; and/or making any commercial use of UB-04 manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.